Form 4: Cidara Therapeutics Executive Acquires Stock Options
SEC Filing
Leslie Tari, Chief Scientific Officer of Cidara Therapeutics, acquired stock options on September 30, 2024.
Summary
- Leslie Tari, the Chief Scientific Officer of Cidara Therapeutics, filed a Form 4 on October 2, 2024, reporting a transaction.
- On September 30, 2024, Tari acquired 150,224 employee stock options with an exercise price of $10.75.
- These options vest in 36 equal monthly installments starting from September 30, 2024, and expire on September 29, 2034.
- Following the transaction, Tari directly owns 150,224 derivative securities.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to monitor executive compensation and potential alignment of interests.
Key Dates
| Date | Description |
|---|---|
| 09/30/2024 | Date of earliest transaction: Tari acquired stock options; Vesting Commencement Date |
| 09/29/2034 | Expiration date of the stock options |
| 10/02/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.